Compare Costco Wholesale Corporation (COST) vs Cronos Group Inc (CRON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Cronos Group Inc — how do they compare? Costco Wholesale Corporation trades at $946.02 (market cap $420.05B), while Cronos Group Inc trades at $3.23 (market cap $1.18B). The key difference: Costco Wholesale Corporation is far larger — about 356× Cronos Group Inc's market cap, and Costco Wholesale Corporation pays a 0.62% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Costco Wholesale Corporation for 132 Days and Cronos Group Inc for 22 Days on average.
| COST | CRON | |
|---|---|---|
Market Cap | $420.05B | $1.18B |
Volume | 2,087,565 | 968,037 |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $3.55 |
52-Week Low | $849.63 | $2.30 |
Typical Hold Time | 132 Days | 22 Days |
Enterprise Value | $407.33B | $387.62M |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco Wholesale Corporation (COST) trades at $942.25, up 0.7% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong March 2026 sales growth of 11.3% year-over-year, and fiscal 2025 revenue reached $275.24 billion with net income of $8.10 billion. Analyst consensus is strongly bullish with a $1,090 price target, though valuation ratios like P/E of 45.39 are elevated.
The outlook remains positive due to membership fee growth and expansion, but risks include high valuation sensitivity and competitive pressures. Earnings momentum is solid with recent beats, supporting the buy-rated sentiment, yet any market pullback could present a better entry point for long-term investors.
CRON trades at $3.24, down 1.37% on the day, with a bearish technical signal and neutral oscillators. The company reported a net loss of $9.45M in 2025 despite revenue growth to $146.59M, but recent quarters show earnings beats. Analyst sentiment is mixed with 20% buy, 60% hold, and 20% sell ratings. Recent news highlights investor day events and international expansion efforts.
The outlook is cautious; profitability improvements and cash flow generation are key catalysts, but high valuation multiples and negative net cash flow pose risks. Regulatory developments in cannabis markets and execution on growth targets will be critical for stock performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →
